Home > Neurology > EAN 2022 > COVID-19 > AstraZeneca vaccination and risk of cerebral venous sinus thrombosis

AstraZeneca vaccination and risk of cerebral venous sinus thrombosis

Presented By
Dr Jonathan Coutinho, Amsterdam University Medical Centre, the Netherlands
EAN 2022
Cerebral venous sinus thrombosis (CVST) was more frequently reported after AstraZeneca (ChAdOx1 nCov-19) vaccination than after any of the other SARS-CoV-2 vaccines, an analysis of cases notified to the European Medicines Agency (EMA) revealed. Patients with CVST after AstraZeneca vaccination had a higher mortality rate compared with pre-COVID-19 CVST controls and patients with CVST after mRNA vaccination. When the first cases were reported of CVST with thrombocytopenia after vaccination against SARS-CoV-2 infection, without any known causal relationship, a study was quickly initiated to investigate this [1,2]. The study's aim was 2-fold: to report clinical data of patients who developed CVST after SARS-CoV-2 vaccination and to compare data between different vaccines and with a pre-COVID-19 CVST control group. Data was retrieved from the so-called EMA EudraVigilance database. Dr Jonathan Coutinho (Amsterdam University Medi...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on